0001181431-12-061038.txt : 20121129
0001181431-12-061038.hdr.sgml : 20121129
20121129134628
ACCESSION NUMBER: 0001181431-12-061038
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20121127
FILED AS OF DATE: 20121129
DATE AS OF CHANGE: 20121129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CHASE ANTHONY R
CENTRAL INDEX KEY: 0001223756
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 121231209
MAIL ADDRESS:
STREET 1: 10307 PACIFIC CENTER COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: OR
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3450 MONTE VILLA PARKWAY
STREET 2: SUITE 101
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 425-354-5038
MAIL ADDRESS:
STREET 1: 3450 MONTE VILLA PARKWAY
STREET 2: SUITE 101
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
rrd361572.xml
X0306
4
2012-11-27
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001223756
CHASE ANTHONY R
3450 MONTE VILLA PARKWAY, SUITE 101
BOTHELL
WA
98021
1
0
0
0
Common Stock
2012-11-27
4
S
0
1100
29.0368
D
26144
D
Common Stock
2012-11-28
4
S
0
1600
28.1681
D
24544
D
Common Stock
2012-11-28
4
S
0
5700
29.7002
D
18844
D
Common Stock
2012-11-28
4
S
0
1600
30.2056
D
17244
D
This transaction was executed in multiple trades in prices ranging from $29.00 to $29.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $27.79 to $28.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $29.35 to $29.95, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $30.00 to $30.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
/s/ Anthony R. Chase
2012-11-28